The kidney cancer treatment landscape has vastly changed in the past 6 years offering many treatment options and more coming ~ new drugs and combination therapies.
The access to new treatment options and understanding what might be right for you can be confusing for patients and their caregivers when making decisions with their health care professionals.
The Kidney Cancer Research Network of Canada recently updated the Consensus for the Management of Advanced Kidney Cancer (2021).
Dr. Christina Canil from The Ottawa Hospital Cancer Centre and lead Medical Oncologist on the consensus statement joins us to explain the updated information and help navigate what options are available to the Canadian kidney cancer community.See consensus statement here
ABOUT THE SPEAKER
CHRISTINA CANIL, MD FRCPC
Assistant Professor of Medicine, University of Ottawa
Division of Medical Oncology
Dr. Christina Canil graduated from the University of British Columbia with a Bachelor of Science majoring in Microbiology. She completed medical school and her internal medicine residency at the University of Toronto and her Medical Oncology residency at McMaster University in Hamilton. Dr. Canil went on to complete a two-year clinical research fellowship at the Princess Margaret Hospital in Toronto, with a focus on genitourinary (GU) cancers. She is a staff Medical Oncologist at the Ottawa Hospital Cancer Centre and an Assistant Professor in the Faculty of Medicine at the University of Ottawa. Her clinical research interests include drug development and survivorship in GU cancers. She is a member of the Cancer Care Ontario Program in Evidence-Based Care GU Cancer Disease Site Group. Dr. Canil is a co-lead with Dr. Jennifer Jones for the survivorship initiative of the Kidney Cancer Research Network of Canada.